VEGFA and neoplasm: Emerging evidence also suggests that homologous recombination deficiency (HRD) promotes genomic instability and tumour hypoxia, resulting in pro‐angiogenic signalling, while concurrent VEGF pathway inhibition can further exacerbate DNA damage and potentiate PARP inhibitor (PARPi) sensitivity.14